<DOC>
	<DOCNO>NCT00523744</DOCNO>
	<brief_summary>This study evaluate efficacy safety valsartan amlodipine fix dose combination adult moderate , inadequately control hypertension . There optional study extension eligible patient want participate contains triple therapy ( ie , hydrochlorothiazide+ amlodipine/valsartan ) .</brief_summary>
	<brief_title>Efficacy Safety Valsartan Amlodipine ( Â± HCTZ ) Adults With Moderate , Inadequately Controlled Hypertension</brief_title>
	<detailed_description>Title study extension : An open-label , multicenter extension evaluate efficacy tolerability 4 week therapy hydrochlorothiazide 12.5 mg plus amlodipine 10 mg/valsartan 160 mg hypertensive patient adequately respond 4 week therapy combination olmesartan 20 mg plus amlodipine 10 mg follow amlodipine 10 mg/valsartan 160 mg</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Amlodipine , Valsartan Drug Combination</mesh_term>
	<mesh_term>Angiotensin Receptor Antagonists</mesh_term>
	<criteria>Inclusion Criteria Core study : Male female patient ( &gt; =18 year ) Females must either postmenopausal one year , surgically sterile use effective contraceptive method Patients essential hypertension ( diastolic blood pressure &gt; =100 mmHg &lt; 110 mmHg ) Inclusion Criteria Extension : Patients msSBP &gt; = 140 mmHg and/or msDBP &gt; = 90 mmHg week 8 ie , end core study . Exclusion Criteria Core study : Severe hypertension ( diastolic blood pressure &gt; =110 mmHg systolic blood pressure &gt; = 180 mmHg ) Pregnant nurse woman Treated hypertensive patient control hypertension current therapy A history cardiovascular disease , include angina pectoris , myocardial infarction , coronary artery bypass graft , percutaneous transluminal coronary angioplasty , transient ischemic attack , stroke , heart failure NYHA II IV Exclusion Criteria Extension : prematurely discontinue core study fail comply core study protocol Other protocoldefined inclusion/exclusion criterion apply study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>hypertension , valsartan , amlodipine</keyword>
</DOC>